OncoMatch/Clinical Trials/NCT05613023
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
Is NCT05613023 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for prostate cancer.
This study will compare the safety and efficacy of curative radiotherapy to the prostate and lymph glands given in 5 visits to that of prostate alone radiotherapy given in 5 visits, in men with high risk localised prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Grade: Gleason 8-10ISUP grade group 4ISUP grade group 5 (Gleason/ISUP)
High risk localised prostate cancer as defined by * Gleason 8-10 (grade groups 4 and 5) and/or * Stage T3a/b or T4
Performance status
WHO 0–2
Prior therapy
Cannot have received: active treatment for prostate cancer
Previous active treatment for prostate cancer
Cannot have received: chemotherapy
Exception: within 6 weeks of the start of radiotherapy
Patients who have had chemotherapy within 6 weeks of the start of radiotherapy.
Cannot have received: pelvic radiotherapy
prior pelvic radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify